Intra-Cellular Therapies Total Revenue

Intra-Cellular Therapies (ITCI) currently reports a total revenue of $680M as of December 2024. That compares with $460M in the prior-year period — up 47.3% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Intra-Cellular Therapies's total revenue history and peer comparisons.

Intra-Cellular Therapies's total revenue increased from $460M to $680M — a 47.3% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intra-Cellular Therapies's total revenue of $680M is lower than the Healthcare sector average of $110B. That is roughly 99.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Intra-Cellular Therapies reported $680M in total revenue as of December 2024. That compares with $460M in the prior-year period — up 47.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $680M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.